Telix and Regeneron Forge Strategic Alliance for Next-Gen Radiopharmaceuticals

Telix Pharmaceuticals Limited and Regeneron Pharmaceuticals have announced a strategic partnership aimed at advancing the development and commercialization of next-generation radiopharmaceutical therapies. The alliance seeks to merge Telix's specialized manufacturing and supply chain infrastructure with Regeneron's advanced biologics and bispecific antibody discovery capabilities. The collaboration will specifically target multiple solid tumors using Regeneron's antibody portfolio, which is developed via VelocImmune® mice. Beyond therapeutics, the companies intend to create radio-diagnostics to improve patient selection and monitor treatment responses, pushing the boundaries of precision oncology. Under the agreement, Regeneron will provide Telix with an initial cash payment of US$40 million to cover four therapeutic programs. Regeneron maintains the option to expand the scope to four additional programs. While the default model involves equal sharing of global costs and profits, Telix may opt out of co-funding for specific programs in exchange for milestones totaling up to US$535 million and low double-digit royalties on net sales. The announcement has triggered a positive response in the markets, with Telix (TLX.AX) shares rising 8.40% to A$15.87. The partnership positions both firms to capture a larger share of the growing radiopharmaceutical market by integrating diagnostic and therapeutic assets.